This could also guide further therapeutic decisions, as some studies showed benefits of using anti-angiogenic drug or chemotherapy with EGFR-TKI vs. EGFR-TKI plus placebo in EGFR- and TP53-positive NSCLC [15,16]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.